8-K/A: SeaStar Medical Adjusts Reverse Stock Split Date

SeaStar Medical Holding Corporation announced a revised effective date for its 1-for-10 reverse stock split, now set for January 5, 2026, to meet Nasdaq listing requirements.

Summary

• SeaStar Medical Holding Corporation changed the effective date of its 1-for-10 reverse stock split from January 2, 2026, to January 5, 2026.
• The reverse stock split was approved by stockholders on December 18, 2025, and by the Board of Directors.
• The primary objective of the reverse split is to increase the market price of the common stock to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
• Shares will begin trading on a split-adjusted basis on The Nasdaq Capital Market on January 5, 2026, under the existing ticker symbol "ICU".
• Every 10 pre-split shares of common stock will be automatically combined and converted into one issued and outstanding share of common stock.
• Fractional shares will not be issued; instead, the number of shares will be rounded up to the next whole number.
• The reverse split will not modify the rights or preferences of the common stock.
• Approximately 3.8 million shares of common stock will be issued and outstanding immediately after the reverse split becomes effective.
• All outstanding stock options and warrants will be proportionally adjusted, including their exercise prices.
• A new CUSIP number, 81256L302, will be assigned to the common stock.

Sentiment

Score: 4

Explanation: While the reverse split addresses a critical compliance issue (Nasdaq listing), it's a reactive measure to a low stock price, which is generally a negative indicator. The delay in the effective date is minor. The underlying business has promising FDA approvals and designations, but the need for a reverse split suggests market skepticism or operational challenges.

Positives

• The reverse stock split aims to help the company regain compliance with Nasdaq's minimum bid price requirement, potentially preventing delisting and maintaining market access.
• Stockholders who would otherwise receive fractional shares will have their shares rounded up to one whole share, which is a benefit.
• The company's QUELIMMUNE (SCD-PED) therapy received FDA approval in 2024 for life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients.
• The Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation by the FDA for six therapeutic indications, potentially enabling a speedier pathway to approval and preferable reimbursement dynamics.

Negatives

• The necessity of a reverse stock split indicates that the company's stock price has fallen below Nasdaq's minimum bid price requirement, suggesting underlying performance or market perception challenges.
• Reverse stock splits can sometimes be perceived negatively by investors, potentially signaling financial distress or a lack of confidence in organic price appreciation.

Risks

• Risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates.
• Risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials.
• Risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators.
• Risk that SeaStar Medical may never achieve or sustain profitability.
• Risk that SeaStar Medical may not be able to secure additional financing on acceptable terms.
• Risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations.
• Risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical's products and services.
• Risk that SeaStar Medical is unable to secure or protect its intellectual property.

Future Outlook

The company expects the reverse stock split to enable it to regain compliance with Nasdaq's $1.00 minimum bid price requirement. It also continues to pursue regulatory approvals and commercialization of its SCD product candidates, including the NEUTRALIZE-AKI pivotal trial for adult AKI patients.

Management Comments

• The objective of the Reverse Split is to increase the market price for the Company's common stock to, among things, enable the Company to regain compliance with the $1.00 minimum bid price requirement under applicable Nasdaq Listing Rules.

Industry Context

Reverse stock splits are a common strategy for companies whose stock price has fallen below exchange minimums, such as Nasdaq's $1.00 bid price rule. This action is typically taken to avoid delisting and maintain investor confidence by presenting a higher per-share price, although it does not change the company's underlying market capitalization or intrinsic value. For a commercial-stage healthcare company like SeaStar Medical, maintaining Nasdaq listing is crucial for liquidity and access to capital markets, especially as it develops and commercializes its specialized therapies for organ failure.

Comparison to Industry Standards

• Many companies facing delisting from major exchanges like Nasdaq due to low share price often resort to reverse stock splits; the 1-for-10 ratio is a common range for such splits, aiming to bring the share price comfortably above the minimum threshold.
• Other biotech or small-cap healthcare companies that have performed reverse splits to maintain listing include Athersys (ATHX), Sorrento Therapeutics (SRNEQ), and Sesen Bio (SESN).
• The company's focus on FDA-approved and Breakthrough Device designated therapies for critical conditions like AKI positions it within a high-risk, high-reward segment of the healthcare industry, where maintaining public listing is vital for funding ongoing trials and commercialization efforts.

Stakeholder Impact

• Shareholders: Will own fewer shares but at a proportionally higher price per share, with no change to their overall equity value immediately after the split. Fractional shares are rounded up. The primary impact is the potential for continued Nasdaq listing, which benefits liquidity.
• Employees: No direct impact mentioned, but maintaining Nasdaq listing can contribute to company stability and access to capital, indirectly benefiting employees.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned, but the risk of third-party suppliers not meeting obligations is noted.
• Creditors: No direct impact mentioned, but the company's ability to raise capital (a risk mentioned) could affect its financial health and ability to meet obligations.

Next Steps

• Common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market on January 5, 2026.
• Stockholders of record will receive information regarding their share ownership following the reverse stock split from Continental Stock Transfer and Trust Company.
• The company will continue its NEUTRALIZE-AKI pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT).
• The company will continue efforts to obtain regulatory approval for its SCD product candidates and commercialize its products.

Key Dates

Recommendation

The reverse stock split is a necessary action to maintain Nasdaq listing, which is a positive for the company's long-term viability and access to capital. However, it doesn't fundamentally change the company's valuation or address the reasons for the low stock price. The company has promising FDA-approved and designated products, but also significant risks related to capital, regulatory approval, and profitability. For a seasoned investor, this filing suggests a "hold" position, awaiting further operational and financial performance updates to assess the effectiveness of the split and the progress of its clinical trials and commercialization efforts. The immediate impact is administrative, but the underlying challenges remain.

Keywords

SeaStar Medical, ICU, Reverse Stock Split, Nasdaq Compliance, Stock Split, Healthcare, Medical Devices, AKI, Sepsis, FDA Approval, QUELIMMUNE, SCD Therapy, Biotechnology